Expression of RBMS3 in Breast Cancer Progression

Abstract

The aim of the study was to evaluate the localization and intensity of RNA-binding motif single-stranded-interacting protein 3 (RBMS3) expression in clinical material using immunohistochemical (IHC) reactions in cases of ductal breast cancer (in vivo), and to determine the level of RBMS3 expression at both the protein and mRNA levels in breast cancer cell lines (in vitro). Moreover, the data obtained in the in vivo and in vitro studies were correlated with the clinicopathological profiles of the patients. Material for the IHC studies comprised 490 invasive ductal carcinoma (IDC) cases and 26 mastopathy tissues. Western blot and RT-qPCR were performed on four breast cancer cell lines (MCF-7, BT-474, SK-BR-3 and MDA-MB-231) and the HME1-hTERT (Me16C) normal immortalized breast epithelial cell line (control). The Kaplan–Meier plotter tool was employed to analyze the predictive value of overall survival of RBMS3 expression at the mRNA level. Cytoplasmatic RBMS3 IHC expression was observed in breast cancer cells and stromal cells. The statistical analysis revealed a significantly decreased RBMS3 expression in the cancer specimens when compared with the mastopathy tissues (p < 0.001). An increased expression of RBMS3 was corelated with HER2(+) cancer specimens (p < 0.05) and ER(−) cancer specimens (p < 0.05). In addition, a statistically significant higher expression of RBMS3 was observed in cancer stromal cells in comparison to the control and cancer cells (p < 0.0001). The statistical analysis demonstrated a significantly higher expression of RBMS3 mRNA in the SK-BR-3 cell line compared with all other cell lines (p < 0.05). A positive correlation was revealed between the expression of RBMS3, at both the mRNA and protein levels, and longer overall survival. The differences in the expression of RBMS3 in cancer cells (both in vivo and in vitro) and the stroma of breast cancer with regard to the molecular status of the tumor may indicate that RBMS3 could be a potential novel target for the development of personalized methods of treatment. RBMS3 can be an indicator of longer overall survival for potential use in breast cancer diagnostic process.

Tumor suppressor function of RBMS3 overexpression in EOC associated with immune cell infiltration

“…It is thought that RBMS3 may be a tumor suppressor since tumor tissues and cells, such as nasopharyngeal carcinoma [ 29 , 30 ], breast cancer [ 31 ], and lung cancer [ 24 ], express less of this protein. The current research verified that RBMS3 was dramatically downregulated in the tissues of EOC patients.…”

New insights into the role of the CHI3L2 protein in invasive ductal breast carcinoma: the CHI3L1 protein has a different role

“…Human cancer cell lines were cultured from various clinicopathological breast tumors, including MCF-7, SK-BR-3, T-47D, BT-474, B-T549, MDA-MB-231, MDA-MB-436, MDA-MB-468, and BO2 (all from ATCC, American Type Culture Collection ATCC, Old Town Manassas, VA, USA) [25], [26]. The MCF10A cell line, which is derived from brocystic breast disease, and the HME1-hTERT (Me16C) (ATCC) cell line, which is normal mammary epithelial cells immortalized with hTERT, were also used.…”

Emerging roles ofRNAbinding proteins in intervertebral disc degeneration and osteoarthritis

“…RBMS3 is a tumor suppressor gene, and downregulation of RBMS3 is correlated with poor prognosis in in various human cancers 144,145 . The suppressive effect of RBMS3 is mediated by a domain located at the 3p region of chromosome 3 that generates multiple tumor suppressor genes 146,147 . It is a favorable prognostic marker for many human cancers.…”

“… 144 , 145 The suppressive effect of RBMS3 is mediated by a domain located at the 3p region of chromosome 3 that generates multiple tumor suppressor genes. 146 , 147 It is a favorable prognostic marker for many human cancers. RBMS3 has been reported to be involved in the promotion of fibrosis and the formation of RBMS3.…”